The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509 and a poly(meth)acrylate copolymer. In one aspect, the solid dispersion of ARN-509 and a poly(meth)acrylate copolymer is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509 and a poly(meth)acrylate copolymer and optionally subsequently milling said melt-extruded mixture. In one aspect, the solid dispersion of ARN-509 and a poly(meth)acrylate copolymer is obtainable, in particular is obtained, by spray drying a mixture comprising ARN-509 and a poly(meth)acrylate copolymer in a suitable solvent.本發明涉及ARN-509的藥物配製物，它們可以被給予罹患以下項的哺乳動物，特別是人：雄激素受體(AR)相關疾病或病症，特別是癌症，更特別是前列腺癌，包括但不限於去勢抵抗性前列腺癌、轉移性去勢抵抗性前列腺癌、化療初治轉移性去勢抵抗性前列腺癌、生化復發型激素敏感性前列腺癌、或者高風險非轉移性去勢抵抗性前列腺癌。在一個方面中，該等配製物包括ARN-509和聚(甲基)丙烯酸酯共聚物的固體分散體。在一個方面中，ARN-509和聚(甲基)丙烯酸酯共聚物的固體分散體係可藉由熔融擠出一包括ARN-509和聚(甲基)丙烯酸酯共聚物之混合物並可隨意地隨後碾磨所述熔融擠出的混合物獲得的，特別是藉由這樣做而獲得。在一個方面中，ARN-509和聚(甲基)丙烯酸酯共聚物之固體分散體係可藉由噴霧乾燥一包括ARN-509和聚(甲基)丙烯酸酯共聚物於適合的溶劑中的混合物獲得的，特別是藉由這樣做而獲得。
